~~<i id='CAD6A2A843'><strike id='CAD6A2A843'><tt id='CAD6A2A843'><pre id='CAD6A2A843'></pre></tt></strike></i>~~

Home» knowledge» comprehensive

comprehensive

author：hotspot 2025-10-02 02:40:43 Page View：762

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Health AI adoption puts security, privacy startups on investors' radar
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Orchard's therapy for neuron disease in children wins FDA approval

AdobeTheFoodandDrugAdministrationonMondayapprovedagenetherapyformetachromaticleukodystrophy,adevasta

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Why is France rioting? What to know about the fatal police shooting of Nahel M

1:17FrenchpoliceofficerspatrolinfrontoftheArcdeTriompheintheChampsElyseesareaofParis,France,onJuly1,